María José Acuña

María José Acuña

Auto-generated profile, based on publicly available information

María José Acuña

Center for Aging and Regeneration, CARE Chile UC and Department Cell and Molecular Biology, Faculty of Biological Sciences, Catholic University of Chile, Santiago, Chile

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2013 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
MAMaría José Acuña
María José Acuña
PPPatrizia Pessina
Patrizia Pessina
HOHugo Olguin
Hugo Olguin
DCDaniel Cabrera
Daniel Cabrera
CVCarlos P. Vio
Carlos P. Vio
EBEnrique Brandan
Enrique Brandan
Duchenne muscular dystrophy (DMD) is the most common inherited neuromuscular disease, and is characterized by the lack of dystrophin, muscle wasting, increased transforming growth factor (TGF)-β Smad-dependent signalling and fibrosis. Acting via the Mas receptor, angiotensin-1-7 [Ang-(1-7)], is part of the renin–angiotensin system, with the opposite effect to that of angiotensin II. We hypothesized that the Ang-(1-7)/Mas receptor axis might protect chronically damaged tissues as in skeletal muscle of the DMD mouse model mdx. Infusion or oral administration of Ang-(1-7) in mdx mice normalized skeletal muscle architecture, decreased local fibrosis and improved muscle function in vitro and in vivo. These positive effects were mediated by the inhibition of TGF-β Smad signalling, which in turn led to reduction of the pro-fibrotic microRNA miR-21 concomitant with a reduction in the number of TCF4 expressing fibroblasts. Mdx mice infused with Mas antagonist (A-779) and mdx deficient for the Mas receptor showed highly deteriorated muscular architecture, increased fibrosis and TGF-β signalling with diminished muscle strength. These results suggest that this novel compound Ang-(1-7) might be used to improve quality of life and delay death in individuals with DMD and this drug should be investigated in further pre-clinical trials.

1 November 2012 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
MMMaría Gabriela Morales
María Gabriela Morales
YVYaneisi Vazquez
Yaneisi Vazquez
MAMaría José Acuña
María José Acuña
JRJuan Carlos Rivera
Juan Carlos Rivera
FSFelipe Simon
Felipe Simon
CCClaudio Cabello-Verrugio
Claudio Cabello-Verrugio

1 February 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
CCClaudio Cabello-Verrugio
Claudio Cabello-Verrugio
CSCristian Santander
Cristian Santander
CCCatalina Cofré
Catalina Cofré
MAMaria José Acuña
Maria José Acuña
FMFrancisco Melo
Francisco Melo
EBEnrique Brandan
Enrique Brandan
Decorin is a small proteoglycan, composed of 12 leucine-rich repeats (LRRs) that modulates the activity of transforming growth factor type β (TGF-β) and other growth factors, and thereby influences proliferation and differentiation in a wide array of physiological and pathological processes, such as fibrosis, in several tissues and organs. Previously we described two novel modulators of the TGF-β-dependent signaling pathway: LDL receptor-related protein (LRP-1) and decorin. Here we have determined the regions in decorin that are responsible for interaction with LRP-1 and are involved in TGF-β-dependent binding and signaling. Specifically, we used decorin deletion mutants, as well as peptides derived from internal LRR regions, to determine the LRRs responsible for these decorin functions. Our results indicate that LRR6 and LRR5 participate in the interaction with LRP-1 and TGF-β as well as in its dependent signaling. Furthermore, the internal region (LRR6i), composed of 11 amino acids, is responsible for decorin binding to LRP-1 and subsequent TGF-β-dependent signaling. Furthermore, using an in vivo approach, we also demonstrate that the LRR6 region of decorin can inhibit TGF-β mediated action in response to skeletal muscle injury.

1 January 2016 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
MMMaría Gabriela Morales
María Gabriela Morales
JAJohanna Abrigo
Johanna Abrigo
MAMaría José Acuña
María José Acuña
Robson SantosRobson Santos
Robson Santos
MBMichael Bader
Michael Bader
CCClaudio Cabello-Verrugio
Claudio Cabello-Verrugio
Immobilization is a form of disuse characterized by a loss of strength and muscle mass. Among the main features are decreased IGF-1/Akt signalling and increased ubiquitin-proteasome pathway signalling, which induce greater myosin heavy chain degradation. Activation of the classical renin-angiotensin system (RAS) causes deleterious effects in skeletal muscle, including muscle wasting. In contrast, angiotensin-(1-7) [Ang-(1-7)], a peptide of the non-classical RAS, produces beneficial effects in skeletal muscle. However, the role of Ang-(1-7) in skeletal muscle disuse atrophy and independent of classical RAS activation has not been evaluated. Therefore, we assessed the functions of Ang-(1-7) and the Mas receptor in disuse muscle atrophy in vivo using unilateral cast immobilization of the hind limb in male, 12-week-old wild-type (WT) and Mas knockout (Mas KO) mice for 1 and 14 days. Additionally, we evaluated the participation of IGF-1/IGFR-1/Akt signalling and ubiquitin-proteasome pathway expression on the effects of Ang-(1-7) immobilization-induced muscle atrophy. Our results found that Ang-(1-7) prevented decreased muscle strength and reduced myofibre diameter, myosin heavy chain levels, and the induction of atrogin-1 and MuRF-1 expressions, all of which normally occur during immobilization. Analyses indicated that Ang-(1-7) increases IGF-1/IGFR-1/Akt pathway signalling through IGFR-1 and Akt phosphorylation, and the concomitant activation of two downstream targets of Akt, p70S6K and FoxO3. These anti-atrophic effects of Ang-(1-7) were not observed in Mas KO mice, indicating crucial participation of the Mas receptor. This report is the first to propose anti-atrophic effects of Ang-(1-7) via the Mas receptor and the participation of the IGF-1/IGFR-1/Akt/p70S6K/FoxO3 mechanism in disuse skeletal muscle atrophy.

12 June 2011 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
CCClaudio Cabello-Verrugio
Claudio Cabello-Verrugio
MAMaría José Acuña
María José Acuña
MMMaría Gabriela Morales
María Gabriela Morales
ABAlvaro Becerra
Alvaro Becerra
FSFelipe Simon
Felipe Simon
EBEnrique Brandan
Enrique Brandan

2 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CRCecilia Riquelme
Cecilia Riquelme
MAMaría José Acuña
María José Acuña
JTJaviera Torrejón
Javiera Torrejón
DRDaniela Rebolledo
Daniela Rebolledo
DCDaniel Cabrera
Daniel Cabrera
EBEnrique Brandan
Enrique Brandan
Duchenne muscular dystrophy (DMD) is the most common inherited neuromuscular disease and is characterized by absence of the cytoskeletal protein dystrophin, muscle wasting, and fibrosis. We previously demonstrated that systemic infusion or oral administration of angiotensin-(1-7) (Ang-(1-7)), a peptide with opposing effects to angiotensin II, normalized skeletal muscle architecture, decreased local fibrosis, and improved muscle function in mdx mice, a dystrophic model for DMD. In this study, we investigated the presence, activity, and localization of ACE2, the enzyme responsible for Ang-(1-7) production, in wild type (wt) and mdx skeletal muscle and in a model of induced chronic damage in wt mice. All dystrophic muscles studied showed higher ACE2 activity than wt muscle. Immunolocalization studies indicated that ACE2 was localized mainly at the sarcolemma and, to a lesser extent, associated with interstitial cells. Similar results were observed in the model of chronic damage in the tibialis anterior (TA) muscle. Furthermore, we evaluated the effect of ACE2 overexpression in mdx TA muscle using an adenovirus containing human ACE2 sequence and showed that expression of ACE2 reduced the fibrosis associated with TA dystrophic muscles. Moreover, we observed fewer inflammatory cells infiltrating the mdx muscle. Finally, mdx gastrocnemius muscles from mice infused with Ang-(1-7), which decreases fibrosis, contain less ACE2 associated with the muscle. This is the first evidence supporting ACE2 as an important therapeutic target to improve the dystrophic skeletal muscle phenotype.